A therapeutic trial of gangliosides and thymosin in the Wobbler mouse model of motor neuron disease.
Mixed bovine gangliosides have been reported to enhance neuronal regeneration and sprouting. The Wobbler mouse model of motor neuron disease was used to test the clinical effects of long-term ganglioside administration on the course of the disease. Mixed gangliosides were injected subcutaneously into a group of 5 Wobbler mice and compared to a control group of 5 Wobbler mice which received saline. Because of several reports implicating involvement of the immune system in ALS, a 3rd group of 5 Wobbler mice received thymosin. All mice were 4 weeks old at commencement of injections. The 3 groups were examined weekly and graded with respect to front leg power, ability to climb a vertical grating, and walking posture. After 4 months of treatment, no significant difference between either experimental group and the controls was found.
D000818:Animals; D001835:Body Weight; D004353:Drug Evaluation, Preclinical; D005732:Gangliosides / Q000502:physiology / Q000627:therapeutic use*; D051379:Mice; D008818:Mice, Neurologic Mutants; D009046:Motor Neurons; D009416:Nerve Regeneration; D009468:Neuromuscular Diseases / Q000188:drug therapy*; D013947:Thymosin / Q000627:therapeutic use*
D005732:Gangliosides; D013947:Thymosin